Scott M. Coiante
2021
In 2021, Scott M. Coiante earned a total compensation of $1.7M as Chief Financial Officer at Aprea Therapeutics, a 6% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $155,000 |
---|---|
Option Awards | $627,770 |
Salary | $381,100 |
Stock Awards | $579,000 |
Total | $1,742,870 |
Coiante received $627.8K in option awards, accounting for 36% of the total pay in 2021.
Coiante also received $155K in non-equity incentive plan, $381.1K in salary and $579K in stock awards.
Rankings
In 2021, Scott M. Coiante's compensation ranked 6,607th out of 12,415 executives tracked by ExecPay. In other words, Coiante earned more than 46.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 6,607 | 47th |
Manufacturing | 2,852 | 48th |
Chemicals And Allied Products | 1,255 | 47th |
Drugs | 1,119 | 47th |
Pharmaceutical Preparations | 812 | 48th |
Coiante's colleagues
We found three more compensation records of executives who worked with Scott M. Coiante at Aprea Therapeutics in 2021.
News
Aprea Therapeutics CFO John Hamill's 2023 pay jumps 62% to $908K
April 25, 2024
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020